TP53共突变与免疫微环境对EGFR外显子20插入肺癌结局的影响
该回顾性研究分析了118例EGFR外显子20插入非小细胞肺癌患者,评估常规治疗疗效及分子特征影响。含铂双药与化疗免疫治疗反应率最高(20-25%),中位无进展生存约7个月;PD-(L)1抑制剂疗效有限。TP53突变、脑转移及较低肿瘤CD8/Th1细胞比值与更短生存独立相关。
要点
- 含铂双药与化疗免疫治疗反应率20-25%,中位PFS约7个月,优于单药化疗、EGFR抑制剂和PD-(L)1抑制剂。
- TP53突变和脑转移与含铂双药及EGFR抑制剂治疗下更短PFS相关(HR 3.3-6.1,p<0.01)。
- 更多肿瘤CD8+细胞和更少Th1细胞与更长OS独立相关(p<0.01)。
核心结论
- 含铂双药和化疗免疫治疗活性最高,ORR为20-25%,mPFS约7个月,与细胞毒药物搭档无关,而PD-(L)1抑制剂疗效有限。
- TP53突变、脑转移和较低的肿瘤CD8/Th1细胞比值与更短生存独立相关。
研究设计与样本
- 回顾性分析118例EGFR外显子20插入非小细胞肺癌患者,基于RECIST v1.1评估影像学反应,88例有TP53状态数据。
主要发现
- 含铂双药和化疗免疫治疗反应率相似(20-25%),疾病控制率均为80%,mPFS约7个月,均长于单药化疗(9%、59%、4.1个月)、EGFR抑制剂(0%、46%、3.0个月)和PD-(L)1抑制剂(0%、30%、2.1个月;p<0.05)。
- 总生存不依赖于一线治疗选择,而与更多线数的全身治疗相关(p<0.05)。
- TP53突变和脑转移与含铂双药及EGFR抑制剂治疗下更短PFS相关(HR 3.3-6.1,p<0.01),并与接受这两种治疗患者的更短OS相关(p<0.05)。
- 更多肿瘤CD8+细胞和更少Th1细胞与更长OS独立相关,不受脑转移和TP53状态影响(p<0.01)。
- 结局在外显子20插入位点、培美曲塞(对比其他细胞毒药物)或贝伐珠单抗使用方面未见差异。
关键数值与推荐
- 含铂双药和化疗免疫治疗:反应率20-25%,疾病控制率80%,mPFS约7个月。
- 单药化疗:反应率9%,疾病控制率59%,mPFS 4.1个月。
- EGFR抑制剂:反应率0%,疾病控制率46%,mPFS 3.0个月。
- PD-(L)1抑制剂:反应率0%,疾病控制率30%,mPFS 2.1个月。
- TP53突变和脑转移与含铂双药及EGFR抑制剂治疗下更短PFS相关(HR 3.3-6.1,p<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: EGFR exon20 insertions (ex20ins) are targeted by novel compounds in non-small-cell lung cancer (NSCLC). However, data about outcome under conventional therapies and the influence of molecular features are scarce. PATIENTS AND METHODS: We retrospectively analysed 118 patients with evaluation of radiologic response based on RECIST v1.1. TP53 status was available for 88 cases. RESULTS: Platinum doublets and chemoimmunotherapy showed similar response rates (20-25%), disease control rates (80%) and median progression-free survival (mPFS, ≈7 months), which were longer compared to monochemotherapy (9%, 59%, 4.1 months), EGFR inhibitors (0%, 46%, 3.0) and PD-(L)1 inhibitors (0%, 30%, 2.1; p < 0.05). Overall survival (OS) was not dependent on the choice of first-line treatment, but related to more lines of systemic therapy (p < 0.05). TP53 mutations and brain metastases were associated with shorter PFS under platinum doublets and EGFR inhibitors (HR 3.3-6.1, p < 0.01), and shorter OS for patients receiving both treatments (p < 0.05). More tumour CD8+ and less Th1 cells were associated with longer OS independent of brain and TP53 status (p < 0.01). No difference in outcome was noted according to the ex20ins site and use of pemetrexed (vs. other cytotoxics) or bevacizumab. Long-lasting responses (>1 year) occasionally occurred under EGFR inhibitors for both 'near-' and 'far-loop' variants. CONCLUSIONS: Platinum doublets and chemoimmunotherapy have the highest activity with ORR of 20-25% and mPFS of approximately 7 months, regardless of the cytotoxic partner, while PD-(L)1 inhibitors show limited efficacy. TP53 mutations, brain metastases and a lower tumour CD8/Th1-cell ratio are independently associated with shorter survival.
引用
- Christopoulos P, Kluck K, Kirchner M, et al. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. Eur J Cancer. 2022. PMID: 35598358. doi:10.1016/j.ejca.2022.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。